Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000897 · ClinicalTrials.gov registry record · NA

A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women

A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
42
Enrollment target

NCT00000897 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 42 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000897, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
42 participants
Enrollment target

Study Summary

The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes ZDV. Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased in individuals who use certain methods of birth control. ZDV may also have different effects in men compared to women.

Interventions

  • DRUG Zidovudine

Trial Details

FieldValue
Enrollment Target 42 participants
Phase NA

What the Registry Record Tells You About NCT00000897

The ClinicalTrials.gov registry entry for NCT00000897 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Zidovudine is the first listed.

NCT00000897 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00000897 about?

NCT00000897 is a clinical study titled "A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women". The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes...

What is the current status of trial NCT00000897?

This trial is currently completed. It is a NA study. The enrollment target is 42 participants.

What interventions are being tested in trial NCT00000897?

The interventions under investigation include: Zidovudine (DRUG).

Who is sponsoring clinical trial NCT00000897?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.